In a major breakthrough, researchers have discovered a drug normally used to treat Parkinson's disease, which may be able to delay or prevent a common form of blindness among older people.
Researchers discovered a biological connection between darker pigmented eyes, which are known to be resistant to Age-related macular degeneration (AMD), and increased levels of a chemical called L-DOPA in those eyes. L-DOPA is frequently prescribed for Parkinson's patients.
They reported that patients receiving L-DOPA were significantly less likely to get AMD, and when they did, its onset was significantly delayed.
Senior author Brian McKay of the University of Arizona said that rather than looking at what might cause AMD, they instead wondered why certain people were protected from AMD.
BrightFocus president Stacy Pagos Haller said that this exciting breakthrough showed the power of scientific discovery to give hope to millions of people across the nation and the world.
The study is published in the American Journal of Medicine.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
